Adding linperlisib to chemo for newly diagnosed peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of peripheral T-cell lymphoma (PTCL) — a cancer of certain white blood cells — that is newly diagnosed and not yet treated.
- You are expected to live at least 6 months.
- You must be able to provide a tumor sample (from a previous biopsy or a new one) and have at least one measurable lymphoma spot larger than 1.5 cm on a scan.
- Your overall health should be fairly good (able to do daily activities, with some limitations allowed) and your heart, liver, and kidney function must be within acceptable limits.
- You must be willing to use effective birth control during the study and for 6 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.